

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. P50959RC1	PREDECESSOR SERIAL NO. 09/611,998
	APPLICANT Appelbaum, et al.	
	PREDECESSOR FILING DATE 7/7/00	GROUP

CO-PENDING PATENT APPLICATIONS


Examiner Initial	Attorney Docket No.	US Serial No.	Filing Date	Title	Inventors
W	P50954-1	09/569,648	5/12/00	Methods of Use of Quinolone Compounds Against Pneumococcal and Haemophilus Strains	Appelbaum, et al.
W	P50955R	09/577,723	5/23/00	Methods of Use of Gemifloxacin Compounds Against Fluoroquinolone Resistant Streptococcus Pneumoniae Bacteria	Bast, et al.
	P50956R	09/577,731	5/23/00	Methods of Use of Gemifloxacin Compounds Against Fluoroquinolone Resistant Streptococcus Pneumoniae Bacteria	Bast, et al.
	P50928X1	09/395,492	3/23/01	Methods of Use of Fluoroquinolone Compounds Against Maxillary Sinus Pathogenic Bacteria	Dubois, et al.

EXAMINER <i>W - [Signature]</i>	DATE CONSIDERED <i>9-19-04</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. P50959RC2	PREDECESSOR SERIAL NO. 10/208,082
	APPLICANT Appelbaum, et al.	
	FILING DATE Herewith	GROUP

CO-PENDING PATENT APPLICATIONS

Examiner Initial	Attorney Docket No.	US Serial No.	Filing Date	Title	Inventors
ce	P50954-1D1 (divisional of previously cited 09/569,648)	10/395,461	3/24/03	Methods of Use of Quinolone Compounds Against Pneumococcal and Haemophilus Strains	Appelbaum, et al.
	P50955RC2 (US2003- 0105127A1)	10/323,101	12/18/02	Methods of Use of Gemifloxacin Compounds Against Fluoroquinolone Resistant Streptococcus Pneumoniae Bacteria	Bast, et al.
	P50956RC2 (US2003- 0073695A1)	10/262,826	10/02/02	Methods of Use of Gemifloxacin Compounds Against Fluoroquinolone Resistant Streptococcus Pneumoniae Bacteria	Bast, et al.
	P50928X1C1 (US2003- 0119866A1)	10/300,407	11/23/02	Methods of Use of Fluoroquinolone Compounds Against Maxillary Sinus Pathogenic Bacteria	Dubois, et al.
ce	P50928X1D1C1 (US2003- 0119867A1)	10/325,521	12/19/02	Methods of Use of Fluoroquinolone Compounds Against Maxillary Sinus Pathogenic Bacteria	Dubois, et al.

EXAMINER 	DATE CONSIDERED 9-15-04
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P50959RC2	PREDCESSOR SERIAL NO. 10/208,082
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Appelbaum, et al.	
		FILING DATE Herewith	GROUP 1625

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
RU	AA	5,633,262	5/27/97	Hong et al.			
	AB	5,776,944	7/7/98	Hong et al.			
	AC	5,869,670	2/9/99	Hong et al.			
lu	AD	5,962,468	10/5/99	Hong et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes No	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

10	CA	G. Cormican, "Comparative Antimicrobial and Spectrum Activity of LB20304a, a New Fluorinated Naphthyridone Compound", <u>Abstracts of the 36th ICAAC</u> , 109 Abst F53 (1996)
	CB	J-H. Kwak, "Antimicrobial Activities of LB20304a, a New Quinolone Antibiotic", <u>The Journal of Applied Pharmacology</u> (4) pp. 378-384 (1996)
	CC	M-K. Seo, "Pharmacokinetics of LB20304, a New Fluoroquinolone, in Rats and Dogs", <u>Arch. Pharm. Res.</u> Vol. 19, No. 5, pp. 359-367 (1996)
	CD	C. Yong Hong, et al., "Novel Fluoroquinolone Antibacterial Agents Containing Oxime-Substituted (Aminomethyl) pyrrolidines: Synthesis and Antibacterial Activity of 7-(4-(Aminomethyl)-3-(methoxyimino) pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro [1,8] naphthyridine-3-carboxylic Acid (LB20304)", <u>J. Med. Chem.</u> 40 (22) pp. 3584-3593 (1997)
	CE	M-K. Seo et al., "High Performance Liquid Chromatographic Assay of a New Fluoroquinolone, LB20304, in the Plasma of Rats and Dogs", <u>Arch. Pharm. Res.</u> Vol. 19, No. 6, pp. 554-558 (1996)
	CF	M-J. Ahn, et al., "InVivo Efficacy of LB20304a against Experimental Respiratory Tract Infection in Mice", <u>Yakhak Hoeji</u> Vol. 40, No. 4, pp. 438-441 (1996)
	CG	M-J. Ahn, et al., "Effect of a New Fluoroquinolone LB20304a on Microflora of Caecum in Mice", <u>Yakhak Hoeji</u> Vol 40, No. 3, pp. 343-346 (1996)
	CH	K-S. Paek, et al., "Factors Affecting In Vitro Activity of LB20304, New Fluoroquinolone", <u>Arch. Pharm. Res.</u> Vol. 19, No. 2, pp. 143-147 (1996)
	CI	M-J. Ahn, et al., "Post-Antibiotic Effect of LB20304, A New Quinolone Antibiotic", <u>Yakhak Hoeji</u> Vol. 40, No. 3, pp. 347-350 (1996)
	CJ	F. Marco, et al., "Antimicrobial Activity of LB20304, a Fluoronaphthyridone, Tested Against Anaerobic Bacteria", <u>J. Antimicrobial Chemother</u> Vol. 40, No. 4, pp. 605-607 (1997)
10	CK	K-S. Paek, et al, "Bactericidal Activities of LB20304, a New Fluoroquinolone", <u>Arch. Pharm. Res.</u> Vol. 19, No. 4, pp. 317-320 (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

[illegible]

OTHER DOCUMENTS (including references, abstracts, etc.)		
6		J-I. Oh et al., "In vitro and In vivo Antibacterial Activities of LB20304, a New fluoronaphthyridone," Abstracts of the 35th ICAAC, p. 148, S-122, Abst F205 (1995)
6		Y-K. Kim et al., "Synthesis and Antibacterial Activities of LB20304: A New Fluoronaphthyridone Antibiotic Containing Novel Oxime Functionalized Pyrrolidine," Abstracts of the 35th ICAAC, p. 148, S-122, Abst F204 (1995)
EXAMINER	DATE CONSIDERED	
6-11-03	9-19-03	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P50959RC2	PREDECESSOR SERIAL NO. 10/208,082
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Appelbaum, <i>et al.</i>	
		FILING DATE Herewith	GROUP Unknown

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
10	AA	WO 98/42705	01.10.98	PCT				
10	AB	EP 0 688 772 A1	27.12.95	EPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

10	AC	Appelbaum, "Antimicrobial Resistance in <i>Streptococcus pneumoniae</i> : An Overview," <i>Clinical Infectious Diseases</i> , 15: 77-83 (1992)
	AD	Doern, <i>et al.</i> , "Antimicrobial Resistance of <i>Streptococcus pneumoniae</i> Recovered from Outpatients in the United States during the Winter Months of 1994 to 1995: Results of a 30-Center National Surveillance Study," <i>Antimicrobial Agents and Chemotherapy</i> , 40(5): 1208-1213 (1996).
	AE	Block, <i>et al.</i> , "Penicillin-resistant <i>Streptococcus pneumoniae</i> in acute otitis media: risk factors, susceptibility patterns and antimicrobial management," <i>The Pediatric Infectious Disease Journal</i> , 14(9): 751-759 (1995).
	AF	Friedland, <i>et al.</i> , "Management of Infections Caused By Antibiotic-Resistant <i>Streptococcus pneumoniae</i> ," <i>New England Journal of Medicine</i> , 331(6): 377-382 (1994).
	AG	Jacobs, "Treatment and Diagnosis of Infections Caused by Drug-Resistant <i>Streptococcus pneumoniae</i> ," <i>Clinical Infectious Diseases</i> , 15: 119-127 (1992).
	AH	Pankuch, <i>et al.</i> , "Activity of CP 99.219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci," <i>Journal of Antimicrobial Chemotherapy</i> , 35: 230-232 (1995).
	AI	Jorgensen, <i>et al.</i> , "Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically," <i>NCCLS</i> , 17(2)M7-A4: 1-27 (1997).
	AJ	Oh, <i>et al.</i> , "In Vitro and In Vivo Evaluations of LB20304, a New Fluoronaphthyridone," <i>Antimicrobial Agents and Chemotherapy</i> , 40(6): 1564-1568 (1996).
	AK	Cormican, <i>et al.</i> , "Antimicrobial Activity and Spectrum of LB20304, a Novel Fluoronaphthyridone," <i>Antimicrobial Agents and Chemotherapy</i> , 41(1): 204-211 (1997).
	AL	Hohl, <i>et al.</i> , "International multicenter investigation of LB20304, a new fluoronaphthyridone," <i>Clinical Microbiology and Infection</i> , 4(5): 280-284 (1998).
10	AM	Clark, <i>et al.</i> , "Antipneumococcal Activities of Levofloxacin and Clarithromycin as Determined by Agar Dilution, Microdilution, E-Test, and Disk Diffusion Methodologies," <i>Journal of Clinical Microbiology</i> , 36(12): 3579-3584 (1998).

10 - Deleted

9 - LG 07

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO.	PREDECESSOR SERIAL NO.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>	P50959RC2	0/208,082
	APPLICANT	
	Appelbaum, <i>et al.</i>	
	FILING DATE	GROUP
	Herewith	Unknown

10	AN	Kelly, <i>et al.</i> , "Antipneumococcal Activity of SB 265805 (a New Broad-Spectrum Quinolone)
		Compared with Nine Compounds by MIC," <i>38th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy</i> , Abstract F-87: 254 (1998).
11	AO	Jorgensen, <i>et al.</i> , "Performance Standards for Antimicrobial Disk Susceptibility Tests," <i>NCCLS</i> ,
		17(1)M2-A6: 1-86 (1997).

EXAMINER <i>Yee</i>	DATE CONSIDERED <i>9-19-07</i>
------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

N:\Loretta\Applications\PS's\P50959RC2\1449 Form C2.doc